2016 Q2 Form 10-Q Financial Statement

#000143774916037175 Filed on August 11, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q2
Revenue $2.663M $1.008M
YoY Change 164.19% 740.0%
Cost Of Revenue $479.0K $253.0K
YoY Change 89.33% 1165.0%
Gross Profit $2.184M $755.0K
YoY Change 189.27% 586.36%
Gross Profit Margin 82.01% 74.9%
Selling, General & Admin $4.146M $4.257M
YoY Change -2.61% 158.0%
% of Gross Profit 189.84% 563.84%
Research & Development $278.0K $1.357M
YoY Change -79.51% -39.42%
% of Gross Profit 12.73% 179.74%
Depreciation & Amortization $27.00K $41.00K
YoY Change -34.15% -41.43%
% of Gross Profit 1.24% 5.43%
Operating Expenses $4.424M $5.614M
YoY Change -21.2% 44.32%
Operating Profit -$2.240M -$4.859M
YoY Change -53.9% 28.54%
Interest Expense -$420.0K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$24.00K -$22.00K
YoY Change 9.09% -136.67%
Pretax Income -$2.688M -$4.881M
YoY Change -44.93% 66.59%
Income Tax $2.000K $6.000K
% Of Pretax Income
Net Earnings -$2.690M -$4.887M
YoY Change -44.96% 66.22%
Net Earnings / Revenue -101.01% -484.82%
Basic Earnings Per Share
Diluted Earnings Per Share -$363.0K -$1.845M
COMMON SHARES
Basic Shares Outstanding 7.407M 2.653B
Diluted Shares Outstanding 7.407M 2.653B

Balance Sheet

Concept 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.790M $7.210M
YoY Change -47.43% -37.68%
Cash & Equivalents $3.495M $7.208M
Short-Term Investments
Other Short-Term Assets $3.000K $600.0K
YoY Change -99.5% -9.09%
Inventory $1.115M $1.450M
Prepaid Expenses $474.0K
Receivables $1.490M $390.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $6.574M $9.650M
YoY Change -31.88% -25.08%
LONG-TERM ASSETS
Property, Plant & Equipment $366.0K $380.0K
YoY Change -3.68% -22.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $65.00K $150.0K
YoY Change -56.67% 0.0%
Total Long-Term Assets $431.0K $520.0K
YoY Change -17.12% -17.46%
TOTAL ASSETS
Total Short-Term Assets $6.574M $9.650M
Total Long-Term Assets $431.0K $520.0K
Total Assets $7.005M $10.17M
YoY Change -31.12% -24.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $860.0K $1.780M
YoY Change -51.69% 242.31%
Accrued Expenses $1.915M $760.0K
YoY Change 151.97% -41.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.368M $2.760M
YoY Change 58.26% 36.63%
LONG-TERM LIABILITIES
Long-Term Debt $520.0K $0.00
YoY Change
Other Long-Term Liabilities $4.580M $2.510M
YoY Change 82.47% 10.09%
Total Long-Term Liabilities $5.100M $2.510M
YoY Change 103.19% 10.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.368M $2.760M
Total Long-Term Liabilities $5.100M $2.510M
Total Liabilities $9.472M $5.270M
YoY Change 79.73% 22.84%
SHAREHOLDERS EQUITY
Retained Earnings -$98.29M
YoY Change
Common Stock $92.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.470M $4.900M
YoY Change
Total Liabilities & Shareholders Equity $7.005M $10.17M
YoY Change -31.12% -24.72%

Cashflow Statement

Concept 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$2.690M -$4.887M
YoY Change -44.96% 66.22%
Depreciation, Depletion And Amortization $27.00K $41.00K
YoY Change -34.15% -41.43%
Cash From Operating Activities -$2.660M -$5.420M
YoY Change -50.92% 44.53%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$10.00K
YoY Change 100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$20.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.750M 7.050M
YoY Change -32.62% 14000.0%
NET CHANGE
Cash From Operating Activities -2.660M -5.420M
Cash From Investing Activities -20.00K 0.000
Cash From Financing Activities 4.750M 7.050M
Net Change In Cash 2.070M 1.630M
YoY Change 26.99% -163.67%
FREE CASH FLOW
Cash From Operating Activities -$2.660M -$5.420M
Capital Expenditures -$20.00K -$10.00K
Free Cash Flow -$2.640M -$5.410M
YoY Change -51.2% 44.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 nby Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
253000
CY2015Q4 nby Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
394000
nby Class Of Warrant Or Right Forfeited During Period
ClassOfWarrantOrRightForfeitedDuringPeriod
3000
nby Class Of Warrant Or Right Forfeited During Period Exercise Price
ClassOfWarrantOrRightForfeitedDuringPeriodExercisePrice
78.13
nby Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
2040000
nby Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
1.91
CY2012Q4 nby Excess Fair Value Over Proceeds Received From Purchase
ExcessFairValueOverProceedsReceivedFromPurchase
1000000
nby Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
1000
nby Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
10000
CY2012Q1 nby Minimum Common Stock Closing Bid Price Per Share
MinimumCommonStockClosingBidPricePerShare
66.50
nby Note Receivable Impairment
NoteReceivableImpairment
91000
nby Note Receivable Impairment
NoteReceivableImpairment
CY2007Q3 nby Number Of Subsidiaries
NumberOfSubsidiaries
2
CY2016Q2 nby Prepaid Deposits
PrepaidDeposits
293000
CY2015Q4 nby Prepaid Deposits
PrepaidDeposits
84000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
860000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2483000
CY2016Q2 nby Private Placement Commission Percentage
PrivatePlacementCommissionPercentage
0.06
CY2016Q2 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Number
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber
297
CY2016Q2 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice
30.31
nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm
P6Y
CY2015Q4 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding
388
CY2016Q2 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding
1485
CY2015Q4 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice
32.03
CY2016Q2 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice
8.64
CY2016Q2 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
83000
CY2016Q2 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Number
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber
1460
CY2016Q2 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.71
nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P9Y36D
CY2016Q2 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriod
297
CY2016Q2 nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested In Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriodWeightedAverageGrantDateFairValue
30.31
nby Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedWeightedAverageRemainingContractualTerm
P6Y
nby Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToEmployees
133000
nby Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToEmployees
nby Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Non Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToNonEmployees
21000
nby Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Non Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToNonEmployees
CY2016Q2 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
1490000
CY2015Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
536000
CY2016Q2 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
0
CY2015Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
0
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1915000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1980000
CY2016Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
122000
CY2015Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
150000
CY2016Q2 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
417000
CY2015Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1769000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1702000
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95728000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
85387000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
270000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
503000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
517000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
788000
CY2016Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
22000
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
40000
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3792000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1419000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3792000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1419000
CY2016Q2 us-gaap Assets
Assets
7005000
CY2015Q4 us-gaap Assets
Assets
5077000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
6574000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
4527000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3495000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2385000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5429000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7208000
us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1110000
us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1779000
CY2011Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
33.25
CY2015Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.19
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.97
CY2016Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2039530
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1458000
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3495000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1946000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2913000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9156935
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3486232
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9156935
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3486232
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
92000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
35000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentrations of Credit Risk and Major Partners</div></div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash. The Company maintains deposits of cash with three highly-rated, major financial institutions in the United States.</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Deposits in these banks may exceed the amount of federal insurance provided on such deposits. The Company does not believe it is exposed to significant credit risk due to the financial position of the financial institutions in which these deposits are held. </div></div><div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 7pt 0pt 0.55pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the three months and six months ended June 30, 2016, revenues were derived primarily from sales of Avenova directly to doctors through the Company&#x2019;s webstore and to three distribution partners. During the three months and six months ended June 30, 2015, revenues were derived primarily from one collaboration partner, service revenues and sales of NeutroPhase. </div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 14.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of June 30, 2016, 36% and 15% of accounts receivable were from two distribution partners. As of December 31, 2015, 41% and 18% of accounts receivable were from two distribution partners.&nbsp;</div></div></div></div></div></div></div></div></div></div></div></div></div>
CY2013Q1 us-gaap Contracts Revenue
ContractsRevenue
313000
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
479000
CY2015Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
253000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1090000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
401000
CY2016Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
189000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
189000
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1593000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
170000
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2132000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2248000
CY2016Q2 us-gaap Depreciation
Depreciation
27000
CY2015Q2 us-gaap Depreciation
Depreciation
41000
us-gaap Depreciation
Depreciation
67000
us-gaap Depreciation
Depreciation
82000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
67000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
82000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.84
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.35
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.94
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
331000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
614000
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2800000
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
385000
CY2016Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
424000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
809000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-34000
CY2012Q1 us-gaap Fees And Commissions Other
FeesAndCommissionsOther
313000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1258000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-16000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-193000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
871000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
213000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-74000
us-gaap Interest Paid
InterestPaid
44000
us-gaap Interest Paid
InterestPaid
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3500000
CY2016Q2 us-gaap Gross Profit
GrossProfit
2184000
CY2015Q2 us-gaap Gross Profit
GrossProfit
755000
us-gaap Gross Profit
GrossProfit
3292000
us-gaap Gross Profit
GrossProfit
1145000
CY2016Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2688000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4881000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7765000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9519000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1679000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-286000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
969000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
151000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1306000
CY2016Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
290000
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
482000
CY2016Q2 us-gaap Inventory Net
InventoryNet
1115000
CY2015Q4 us-gaap Inventory Net
InventoryNet
1345000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9932000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-2690000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-4887000
CY2016Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
835000
CY2015Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
660000
CY2016Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
37000
CY2015Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
45000
CY2015Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2016Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
27000
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
248000
us-gaap Inventory Write Down
InventoryWriteDown
37000
us-gaap Inventory Write Down
InventoryWriteDown
CY2016Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
260000
CY2015Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
224000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
513000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
480000
CY2016Q2 us-gaap Liabilities
Liabilities
9472000
CY2015Q4 us-gaap Liabilities
Liabilities
10175000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7005000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5077000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4368000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4633000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8740000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
11696000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-38000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
15000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7592000
us-gaap Net Income Loss
NetIncomeLoss
-7767000
us-gaap Net Income Loss
NetIncomeLoss
-9527000
CY2011Q3 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
139520
CY2016Q2 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
524000
CY2015Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
1655000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
4
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
4389000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
5614000
us-gaap Operating Expenses
OperatingExpenses
10121000
us-gaap Operating Expenses
OperatingExpenses
10665000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2205000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4859000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6829000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9520000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
239000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
232000
CY2016Q2 us-gaap Other Assets Current
OtherAssetsCurrent
3000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
65000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
155000
CY2016Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-424000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-809000
CY2015Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
34000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-59000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-127000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000
CY2016Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
142000
CY2015Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
137000
CY2016Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
9000
CY2015Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
77000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
73000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
123000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
474000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
261000
CY2016Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
474000
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
261000
CY2016Q2 us-gaap Prepaid Insurance
PrepaidInsurance
36000
CY2015Q4 us-gaap Prepaid Insurance
PrepaidInsurance
40000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
366000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
395000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 1.2pt 0pt 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.5pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications </div></div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0.65pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not change total assets, total liabilities, or total stockholders&#x2019; (deficit).</div></div></div></div></div></div></div></div></div></div></div></div></div>
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9875000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1365000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
11696000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
37000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2016Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2016Q2 us-gaap Profit Loss
ProfitLoss
-2690000
CY2015Q2 us-gaap Profit Loss
ProfitLoss
-4887000
us-gaap Profit Loss
ProfitLoss
-7767000
us-gaap Profit Loss
ProfitLoss
-9527000
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2135000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2097000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
15000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
us-gaap Repayments Of Debt
RepaymentsOfDebt
2500000
us-gaap Repayments Of Debt
RepaymentsOfDebt
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
278000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1357000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1211000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2940000
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-98287000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90520000
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
2654000
CY2015Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
931000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
4309000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1423000
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
2663000
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
1008000
us-gaap Sales Revenue Net
SalesRevenueNet
4382000
us-gaap Sales Revenue Net
SalesRevenueNet
1546000
us-gaap Stock Issued1
StockIssued1
4000
us-gaap Stock Issued1
StockIssued1
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1518567
CY2016Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2016Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2853000
CY2015Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2311000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5997000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4225000
us-gaap Share Based Compensation
ShareBasedCompensation
279000
us-gaap Share Based Compensation
ShareBasedCompensation
677000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P1Y335D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
37.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1169
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
84000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.69
us-gaap Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
-84000
us-gaap Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
-111000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y73D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y36D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2016Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2800000
CY2016Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2467000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5098000
CY2016Q2 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
553000
CY2015Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
590000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 1.2pt 0pt 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.5pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates </div></div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0.65pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.<div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>
CY2015Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1450000
CY2016Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1835000
CY2016Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2259000
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7406605000
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2653226000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5746314000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2415361000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7406605
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2653226
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5746314
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2415361
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7406605000
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2653226000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5746314000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2415361000

Files In Submission

Name View Source Status
0001437749-16-037175-index-headers.html Edgar Link pending
0001437749-16-037175-index.html Edgar Link pending
0001437749-16-037175.txt Edgar Link pending
0001437749-16-037175-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nby-20160630.xml Edgar Link completed
nby-20160630.xsd Edgar Link pending
nby-20160630_cal.xml Edgar Link unprocessable
nby-20160630_def.xml Edgar Link unprocessable
nby-20160630_lab.xml Edgar Link unprocessable
nby-20160630_pre.xml Edgar Link unprocessable
nby20160531_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending